*Cole Eye Institute, Cleveland, Ohio; †Retina Foundation of the Southwest, Dallas, Texas; ‡Department of Ophthalmology, UT Southwestern Medical Center, Dallas, Texas; §Novartis Pharmaceuticals Corp, East Hanover, New Jersey; ¶Novartis Pharma AG, Basel, Switzerland; and **Aegis Creative Communications, Inc, Lakewood, Colorado.
Retina. 2013 Oct;33(9):1863-70. doi: 10.1097/IAE.0b013e3182899258.
This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab.
Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT.
Among 160 patients from 24 U.S. centers enrolled in the study (103 [64%] ≥ 75 years of age), 84.7% on average complied with daily mVT testing and ≈ 98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders.
Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.
本初步研究旨在评估健康管理工具（HMT）的可行性，HMT 是一种新型的计算系统，使用移动手持设备，以远程监测接受雷珠单抗治疗的新生血管性年龄相关性黄斑变性患者的视网膜视觉功能。
本前瞻性、开放性、单臂研究共纳入了 16 周内至少 1 只眼患有新生血管性年龄相关性黄斑变性（新诊断或治疗成功<1 年）且符合雷珠单抗治疗条件的患者。患者每天通过 HMT 设备（iPhone 3GS）远程进行形状辨别超敏测试（myVisionTrack [mVT]），并在所有就诊时进行。输入 HMT 设备的数据被收集在 HMT 数据库中，该数据库还会向患者发送 mVT 提醒。
在这项研究中，来自美国 24 个中心的 160 名患者（103 名[64%]≥75 岁）中，平均有 84.7%的患者平均每天进行 mVT 测试，约 98.9%的患者每周至少进行一次 mVT 测试。HMT 数据库成功上传了超过 17000 次 mVT 评估值，并发送了超过 9000 次提醒。
在这种远程视觉监测的新型系统中，患有新生血管性年龄相关性黄斑变性的老年患者愿意且能够每天使用移动手持设备自我测试视网膜视觉功能。
Zotero 插件